Neuroendocrine Carcinoma
📧 Sign up to get email alerts when something new happens for Neuroendocrine Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas [Phase 2]
Phase 2 clinical trial update evaluating niraparib and dostarlimab for small cell lung cancer and other high-grade neuroendocrine carcinomas…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
A completed clinical trial evaluating the use of 68Ga-DOTATATE PET imaging in neuroendocrine carcinoma of the gastrointestinal tract.
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors [Phase 2]
Phase 2 clinical trial evaluating the combination of lenvatinib and pembrolizumab for well-differentiated neuroendocrine tumors is currently…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors [Phase 2]
Phase 2 trial evaluating cabozantinib (XL184) in combination with nivolumab and ipilimumab for poorly differentiated neuroendocrine tumors; …
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI [Phase 2]
Phase 2 trial evaluating dostarlimab for locally advanced or metastatic dMMR/MSI cancers excluding colorectal and endometrial, across multip…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers [Phase 2]
Phase II trial of XmAb20717 for advanced rare cancers has been suspended, with eligibility including microsatellite instability-high cancers…
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies [Phase 1]
Ongoing Phase 1 safety/efficacy trial of CID-078 in patients with advanced/metastatic solid tumors; study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-09-04Clinical Trial Update: Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma [Phase 2]
Phase 2 trial evaluating the combination of sintilimab with surufatinib and temozolomide for advanced neuroendocrine carcinomas is not yet r…
-
CLINICAL_TRIALS trial_result · 2025-09-03Clinical Trial Update: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer [Phase 2]
Phase 2 study assessing bevacizumab in combination with FOLFIRI as second-line therapy for advanced, inoperable poorly differentiated neuroe…
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET [Phase 2]
A Phase 2 trial of iadademstat in combination with paclitaxel for relapsed/refractory small-cell lung cancer and extrapulmonary high-grade n…
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma [Phase 2]
A Phase 2 trial evaluating nab-paclitaxel in combination with bevacizumab for metastatic extrapulmonary neuroendocrine carcinoma has complet…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RO7616789 in advan…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas [Phase 2]
A Phase 2 trial comparing CAPTEM (capecitabine + temozolomide) versus FOLFIRI as second-line therapy for neuroendocrine carcinoma was termin…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma [Phase 2]
A Phase 2 trial evaluating second-line therapy for progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma [Phase 4]
Phase 4 trial evaluating liposomal irinotecan for neuroendocrine tumors. The study is currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors [Phase 2]
Phase II trial of pembrolizumab plus lenvatinib in advanced well-differentiated neuroendocrine tumors has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma [Phase 3]
Phase 3 trial evaluating surufatinib plus toripalimab for advanced neuroendocrine carcinoma is underway, with status currently unknown.
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms [Phase 2]
Phase 2 clinical trial investigating dual 64Cu-DOTATATE and 18F-FDG PET/CT imaging for neuroendocrine neoplasms.
-
CLINICAL_TRIALS trial_result · 2023-05-30Clinical Trial Update: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin [Phase 2]
Phase 2 trial investigating everolimus as maintenance therapy for metastatic neuroendocrine carcinoma of pulmonary or gastroenteropancreatic…
-
CLINICAL_TRIALS trial_result · 2023-04-11Clinical Trial Update: Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma [Phase 2]
Phase 2 clinical trial evaluating a regimen of paclitaxel, carboplatin, and oral etoposide followed by weekly paclitaxel in high-grade neuro…
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. [Phase 1, Phase 2]
A single-arm, open-label clinical trial evaluating surufatinib combined with serplulimab, platinum, and etoposide in neuroendocrine carcinom…
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial update for TEMCAP in grade 3 and low Ki-67 gastroenteropancreatic neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy [Phase 2]
Phase 2 trial evaluating surufatinib plus sintilimab in metastatic neuroendocrine tumors and pancreatic carcinoma after failure of standard …
-
CLINICAL_TRIALS trial_result · 2022-04-12Clinical Trial Update: Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers [Phase 1, Phase 2]
A Phase 1/2 trial update reports completed results for combining topotecan with the ATR inhibitor berzosertib (VX-970/M6620) in small cell c…
-
CLINICAL_TRIALS trial_result · 2022-02-25Clinical Trial Update: Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy [Phase 2]
Phase 2 trial evaluating avelumab in neuroendocrine carcinomas grade 3 after chemotherapy has completed.